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Abstract: Unprecedented efforts in malaria control over the last 15 years have led to a substantial 
decrease in both morbidity and mortality in most endemic settings. However, these progresses have 
stalled over recent years, and resurgence may cause dramatic impact on both morbidity and 
mortality. Nevertheless, elimination efforts are currently going on with the objective of reducing 
malaria morbidity and mortality by 90% and malaria elimination in at least 35 countries by 2030. 
Strengthening surveillance systems is of paramount importance to reach those targets, and the 
integration of molecular and genomic techniques into routine surveillance could substantially 
improve the quality and robustness of data. Techniques such as polymerase chain reaction (PCR) 
and quantitative PCR (qPCR) are increasingly available in malaria endemic countries, whereas 
others such as sequencing are already available in a few laboratories. However, sequencing, 
especially next-generation sequencing (NGS), requires sophisticated infrastructure with adequate 
computing power and highly trained personnel for data analysis that require substantial 
investment. Different techniques will be required for different applications, and cost-effective 
planning must ensure the appropriate use of available resources. The development of national and 
sub-regional reference laboratories could help in minimizing the resources required in terms of 
equipment and trained staff. Concerted efforts from different stakeholders at national, sub-regional, 
and global level are needed to develop the required framework to establish and maintain these 
reference laboratories.  
Keywords: malaria; surveillance; molecular; genomic; Plasmodium falciparum, Plasmodium vivax; 
sequencing. 
 
1. Background 
Malaria remains a major public health problem globally. In 2017, there were approximately 219 
million cases and 435,000 related deaths worldwide, with most cases and deaths in young children 
in sub-Saharan Africa [1]. Nevertheless, there was a tremendous decrease in malaria morbidity and 
mortality between 2000 and 2015, the number of cases and related deaths decreasing by 18% and 48%, 
respectively [2]. At the same time, the number of countries with ongoing malaria transmission 
decreased from 106 to 95, while the number of countries progressing towards malaria elimination, 
i.e., <1000 cases/year, increased from 13 to 33 [2]. All those gains were possible due to unprecedented 
efforts in malaria control by the provision of efficacious control measures including long-lasting 
insecticide-treated bed nests (LLINs) and artemisinin-based combination therapies (ACTs). 
Consequently, the hope that a global eradication is feasible in the foreseen future with sustained 
investment in malaria control remerged, and a strategy of decreasing malaria prevalence by 90% 
globally and elimination of malaria in at least 33 countries was adopted in 2015 by the World Health 
Organization (WHO) [3]. However, this progress has stalled over the last few years, with morbidity 
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and mortality increasing again in some countries between 2015 and 2017 [1]. Therefore, to reach those 
ambitious goals, surveillance systems need to be strengthened, and new tools are needed to improve 
diagnosis of low parasite densities, improve the characterization of the parasite reservoir, and better 
assess transmission to provide precise and robust data for surveillance [4,5]. Indeed, currently 
malaria diagnosis is mainly based on light microscopy (LM) and rapid diagnostic tests (RDTs); 
however, those tools, even though very useful, have some limitations in the elimination context. 
Recently, highly sensitive RDTs (HS-RDTs) have been developed and have been shown to improve 
performance in detecting low-density infections compared to LM or RDTs [6–8]. Nevertheless, more 
sensitive diagnostic tools may be required to detect transmissible very low parasites densities [9–11], 
and the emergence and spread of parasite with HRP2/3 deletion could definitely compromise the use 
of this new HS-RDT in some settings [12,13]. 
By increasing sensitivity more than 10,000× compared to LM and RDTs, molecular techniques 
provide a more sensitive approach to diagnose very low parasite density infections [14], allowing to 
detect asymptomatic carriers who may contribute largely to transmission [15–17]. However, in 
elimination settings, detecting very low-density parasites is not enough to assess transmission at low-
level scale and the impact of interventions. Genomic data may provide a more detailed picture on the 
parasite population structure and fine-scale data that could help customizing interventions [18]. 
Indeed, genomic data can provide information about the parasite population structure at local level, 
allowing for example to differentiate local from imported parasites, detecting foci of transmission, 
characterizing connectivity and transmission of different parasite strains [19,20]. Whole-genome 
sequencing (WGS), targeted amplicon deep sequencing (TADS), and other single nucleotide 
polymorphisms (SNPs)-based genotyping assays such as high-resolution melting (HRM) are very 
powerful tools to assess those dynamics. Indeed, sequencing costs are decreasing, and novel 
techniques have been established to improve and standardize sequencing quality, even from dried 
blood spots (DBS), facilitating the use of the technique in epidemiological and surveillance studies 
[21–23]. Moreover, new analytical methods have also been developed to facilitate the analysis and 
provide meaningful results [24–26]. The integration of epidemiological, molecular, and genomic data 
could substantially improve malaria surveillance in elimination settings [27–29]. However, until now, 
those tools have been essentially used in research settings and rarely in routine surveillance. In this 
review, we describe the advantages and disadvantages of those new techniques and provide 
suggestions on how they could be integrated in routine surveillance in pre-elimination or elimination 
settings.  
2. Molecular Diagnosis 
Various molecular techniques are currently used for malaria diagnosis: Nested polymerase 
chain reaction (nPCR), quantitative PCR (qPCR), quantitative reverse transcriptase PCR (qRT-PCR), 
loop-mediated isothermal amplification (LAMP), and quantitative nucleic acid sequence-based 
amplification (QT-NASBA) [30]. The different techniques with their specific characteristics have their 
advantages and disadvantages and may be appropriate for specific applications (Table 1). However, 
there is clearly a lack of highly sensitive/high throughput point-of-care (POC) molecular test [5], even 
though LAMP may be considered currently as the best available alternative to be used as a molecular 
diagnostic POC tool [31]. Different LAMP technologies have been developed, and sensitivity can go 
as low as 1 to 10 parasites/µl [32]. PCR-based techniques are more sensitive, increasing the sensitivity 
up to 0.022–0.1 parasites/µl [33,34], 0.016 parasites/µl by RT-qPCR [35], or even 0.003362 parasites/µl 
by amplifying total nucleic acids (DNA and RNA) with RT-qPCR [14]. However, those techniques 
are better suited for well-equipped laboratories, with well-trained staff [36]. Those techniques may 
be better indicated for large cross-sectional surveys, for example before and after a campaign of mass 
drug administration (MDA) for baseline surveys and impact assessment [37–39]. New techniques are 
still in development and could complete the portfolio of molecular methods available for malaria 
diagnosis, for example, the PCR nucleic acid lateral flow immunoassay (NALFIA) [40] and 
microfluidics-based assays [41], and could potentially improve the sensitivity and throughput, while 
providing POC molecular diagnostic testing alternatives.  
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Table 1. Characteristics of the different molecular diagnostic techniques used to detect malaria parasites. 1 
Assay Limit of Detection (Parasites/µl) Throughput 
Cost/Sample Excluding 
Labor and Equipment 
(USD) 
Advantages Disadvantages Reference 
Nested PCR 1 moderate <10 
Requires simple and cheap thermocycler 
Can be performed with low amount of DNA 
(e.g., from dried blood spots) 
Moderately sensitive 
 
Requires good laboratory 
infrastructure and well-trained 
staff 
[42] 
qPCR  
(high blood volume) 0.022 high <10 Highly sensitive 
Requires high blood volume 
 
Requires good laboratory 
infrastructure and well-trained 
staff 
[34] 
qPCR  
(low blood volume 
or dried blood 
spots) 
0.15 high <10  
Highly sensitive 
 
Can be performed with low amount of DNA 
(e.g., from dried blood spots) 
Requires good laboratory 
infrastructure and well-trained 
staff 
[33] 
qRT-PCR 0.002 high <20 
Highly sensitive 
 
Can be performed with low amount of DNA 
(e.g., from dried blood spots) 
 
Can detect and quantify gametocytes 
Difficult to work with RNA 
Requires good laboratory 
infrastructure and well-trained 
staff 
 
[14]  
LAMP 1 to 5 moderate <3 
Cheap 
 
Does not require laboratory infrastructure and 
well-trained staff 
 
Can be performed with low of DNA (e.g., 
from dried blood spots) or directly from 
blood sample 
 
Fast 
Moderately sensitive 
 
Limited throughput 
 
[31] 
QT NASBA <1 high  
Can be performed with low amount of DNA 
(e.g., from dried blood spots) 
 
Can detect and quantify gametocytes 
Not as robust as qRT-PCR [43] 
2 
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3. Population Genetics 
Populations’ genetic studies for human malaria parasites (P. falciparum and P. vivax) to assess 
the dynamics of transmission or the relatedness of parasite populations have for long time used 
microsatellites [28,44–46]. Subsequently, other techniques, such as molecular barcode based on 
genotyping of a limited number of SNPs by HRM [29,47,48], high throughput SNPs genotyping on 
the Sequenom MassAarray iPLEX platform, or large scale SNPs genotyping using a custom 384-SNP 
Illumina GoldenGate platform [49,50], have been used. However, the optimal use of microsatellites 
is limited to monoclonal infections, and PCR amplifications of those short tandem repeats often 
produce artefacts that make the data analysis complicated, while the SNP barcode by HRM is limited 
in detecting minority clones [36,51]. Recent studies have used either WGS [27] or TADS [52] to assess 
those dynamics on a finer scale. WGS offers the advantage of providing a full picture of the parasite 
genome and is more suitable for studying foci of transmission with reduced diversity and mainly 
clonal parasites, as the detection of minority clones is limited [53]. WGS is also important in detecting 
new genetic variants associated with antimalarial drug resistance, when molecular markers 
associated with antimalarial drug resistance have not yet been discovered or validated [54,55], and 
may be useful to provide a population prevalence of G6PD deficiency in regions where radical cure 
of P. vivax with 8-aminoquinolines is required [56]. The use of TADS has the advantage of reduced 
cost and work by sequencing a defined genome target, thus allowing the use of very low starting 
DNA material, such as those usually collected from routine surveys on dried blood spots [57] or even 
from RDTs [58]. TADS also has the advantage of detecting minority clones and reconstructing 
haplotypes in multiple clones infections [52,59]. The different techniques may be used for different 
applications in pre-elimination and elimination settings (Figure 1).  
 
Figure 1. Applications for the different genomic techniques for malaria surveillance in pre-elimination 
and elimination settings. A cost-effective way of using whole-genome sequencing would be to use it 
mainly in pre-elimination settings to assess the population genetic structure to help develop 
customized gene-targeted assays to use in elimination settings. 
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4. Discussion 
Malaria elimination and eradication are back on the agenda of the global health community, and 
discussions about their feasibility are going on. The WHO in its global technical strategy 2016–2030 
is aiming at eliminating malaria in 30 countries by 2030 [3]. To reach those ambitious targets, there is 
a need to reassess the current strategies for malaria control and optimize them. One of the main 
changes to move from control to elimination is to include surveillance as a core component in any 
malaria control program [60]. Recent success in malaria elimination, such as in Sri Lanka, have shown 
that well-trained staff, political commitment, and a good surveillance system are key for a successful 
malaria elimination program [61].  
Case detections in malaria elimination settings are still mainly based on LM and RDT. Even 
though those techniques have proved to be successful in some malaria elimination settings, the 
addition of molecular techniques could greatly improve the sensitivity of parasites detection, 
especially for asymptomatic cases [62]. qRT-PCR is currently the most sensitive technique for malaria 
diagnosis but is not practical due to the inherent difficulty in working with RNA, even in well-
equipped laboratories [35]. Therefore qPCR, especially highly sensitive qPCR [9,33,34], would be 
more suitable for malaria diagnosis in reference laboratories with good infrastructure and well-
trained staff (Figure 2). Those laboratories could be at national level for small countries but could be 
also at sub-national level in bigger countries. Ultrasensitive qPCR techniques using finger prick blood 
volume for P. falciparum [33] and P. vivax [63] would be easier to implement compared to the high 
volume qPCR that is more sensitive but would be less practical in routine surveillance due to the 
venipuncture blood [9,34]. Ultrasensitive qPCR could be used, for instance, for baseline surveys 
before MDA or to assess the impact of different interventions [16,38]. QT-NASBA and RT-qPCR 
would have the advantage of being able to detect gametocytes, for example in studies evaluating the 
efficacy of gametocytocidal drugs, or to evaluate the impact of interventions aiming at reducing 
transmission [64–66]. Those different interventions do not require prompt results for case 
management; therefore, the analysis could be easily conducted in a sub-national or national reference 
laboratory. This will ensure good quality data as well, as the laboratories will have time to perform 
the experiments with good quality standards. However, point-of-care tests are lacking for strategies 
such focal screening and treatment (FSAT) or mass screening and treatment (MSAT). In the instance 
LAMP could be used, even though, the low throughput and the lower sensitivity of the technique 
compared to other molecular techniques would probably not provide optimal results, especially for 
asymptomatic cases. LAMP techniques could be used as well at point of care and could help detect 
asymptomatic carriers in passive case detection (PCD), active case detection (ACD), and reactive case 
detection (RACD). As LAMP techniques are more sensitive than microscopy and RDTs, they could 
be in some cases a useful addition to the diagnostic tool box for very low endemic settings [31,32]. 
However, new techniques in development, such as microfluidics-based nucleic acid tests, would be 
better suited for population-based interventions such as FSAT and MSAT, as they would have the 
advantage of increasing the sensitivity, improving the throughput, and in some instances if they are 
multiplexed, could provide information on non-malaria infection for prompt patient care 
management [41].  
One of the recommendations of the malERA expert panel is to improve the characterization of 
the parasite reservoir and develop new tools to assess transmission [4]. Those tools are available and 
are being progressively deployed in malaria endemic countries [67]. Currently HRM genotyping 
using SNPs offers a relatively low-cost, robust, and easy to implement method to study parasite 
population structure and molecular markers associated with antimalarial drug resistance [68,69]. The 
technique could easily be implemented in laboratories in malaria endemic settings, even though it 
would need to be implemented only in reference laboratories with qualified personnel and adequate 
infrastructure. However, NGS methods could potentially provide more information, especially to 
study parasite population structure and dynamics at lower scale level [25,70]. WGS does provide 
complete information about the parasite genetics, but it may not be needed in most cases. WGS would 
be more appropriate in pre-elimination settings to provide insights into the local and/or regional 
parasite populations to guide the selection of the right markers to be used in the elimination phase, 
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and TADS would provide the most useful information in elimination settings and would be more 
cost-effective (Figure 1). The development of long-read sequencing platforms, such as Oxford 
Nanopore Technology (ONT) and Pacific Biosciences (PacBio), could help improve the usefulness of 
sequencing data for surveillance. Though currently limited by their higher error rate compared to 
Illumina sequencing, their capacity of providing long reads up to 10 kb [71–73] could be useful in 
developing long amplicon reads combining molecular markers of resistance and genetic diversity 
SNPs. Moreover, the combination of long- and short-reads sequencing data in the hybrid assembly 
has been show to improve substantially the accuracy of the data [74]. The introduction of genomic 
data could also improve surveillance by providing more sensitive and accurate data on transmission, 
vector and drug resistance, differentiating imported from local infections, or determining 
connectivity of parasite populations [18]. Integrated with epidemiological data, the genetic 
information could help in detecting foci of transmission and customizing the interventions. Indeed, 
this will give information on the dynamics of parasite population in a specific region, allowing better 
targeted interventions. For example, in countries with P. vivax, the radical cure of hypnozoites is of 
great importance. Effective drugs such as primaquine and tafenoquine are available; however, their 
use is limited by the lack of point-of-care test for G6PD-deficient patients [75]. Population-based 
surveys looking at the different mutation variants associated with G6PD deficiency could provide 
useful baseline data for radical cure treatment policy in the absence of a validated POC test [76]. 
Combined with modelling, the genomic information could help predict the distribution and 
dynamics of the parasite population and the spread of resistant parasites and mosquitoes, allowing 
for informed and tailored interventions. To get reliable and complete information from genomic data, 
sample sizes must be adequate for the specific questions asked; the centralization of samples storage 
collected during routine surveillance or case management at reference laboratories could help in 
having access to a large number of samples to analyze if the appropriate metadata are also stored 
appropriately (Figure 2). Data transfer systems using mobile phone-based applications could be 
implemented at the different levels of the health systems for accurate and rapid transmission of 
information to the reference laboratories and the National Malaria Control Program [77–79].  
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Figure 2. Schematic representation describing how reference laboratories for molecular diagnostic 
and genomic analyses could be integrated into routine surveillance for malaria elimination. The 
national malaria control program (NMCP) should coordinate the different activities. All positive 
samples collected during routine case management at health facility or by community health workers 
(CHWs) should be sent directly to the reference laboratory. Samples collected during surveillance 
should be send to regional or national reference laboratory, where they are screened for malaria, and 
positive samples would be then sent to the national or sub-regional reference laboratory. Metadata 
collected during case management of surveillance should be sent directly to NMCP in real-time by 
apps developed specifically for malaria surveillance. 
5. Outlook 
Globally, a consensus has been established that good quality data are required to improve 
disease surveillance, especially in low- and middle-income countries (LMICs) [80]. The establishment 
of well-equipped reference laboratories with well-trained staff in most malaria endemic settings will 
require concerted efforts from different stakeholders, and several challenges ranging from funding 
to staff retention and procurement of required reagents are only a part of them [67,81,82]. However, 
the use of NGS could be centralized to very few sub-regional reference laboratories located in malaria 
endemic countries [36,83,84]. This requires a lot of effort to develop the capacity not only for 
sequencing but more importantly for data analysis, a critical part in the path for developing countries 
to get access to these techniques [85–87]. This should be a concerted effort not only from the malaria 
community but from the global health community, as other diseases such as tuberculosis (TB), human 
immunodeficiency virus (HIV), and other bacterial and viral infections may benefit as well from these 
centers of excellence [88]. The private sector should be involved to support the development of data 
sharing and storage platforms, and that will require clear regulations to be set up by local authorities 
on data privacy and ownership [89,90]. Support from well-established and expert laboratories in 
developed countries would be required, and establishment of sustainable external quality assurance 
(EQA) programs will be of paramount importance [91]. The development of sub-regional center of 
excellence will also require the establishment of samples and data sharing policies between different 
countries, and initiatives such as the Malaria Genomic Epidemiology Network (MalariaGEN) and 
Plasmodium Diversity Network Africa (PDNA) are providing examples of successful platforms for 
collaboration and data sharing [92,93]. It is also crucial that national malaria control programs 
(NMCPs) are playing a central role in these changes (Figure 2), and they must develop clear policies 
based on their needs and resources, provide clear guidance to the collaborating laboratories and the 
different key stakeholders at each level of the health system, and coordinate the different activities. 
With decreasing transmission in some settings and not neighboring regions, imported malaria cases 
will become an increasing threat to elimination, forcing different countries to cooperate. In China for 
example, almost all malaria cases are now imported, not only from neighboring countries, but also 
from Africa [94]. Therefore, it should be easier to convince the malaria stakeholders that approaches 
at the different levels are required, and sub-regional centers of excellence for genomics analyses could 
be a cost-effective way of improving collaborations between countries for the same goal of malaria 
elimination and eradication. 
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